S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
Log in
NASDAQ:ICCC

ImmuCell Stock Forecast, Price & News

$9.08
-0.27 (-2.89 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$8.70
Now: $9.08
$10.03
50-Day Range
$6.26
MA: $9.64
$11.88
52-Week Range
$3.70
Now: $9.08
$13.20
Volume61,977 shs
Average Volume67,786 shs
Market Capitalization$65.49 million
P/E RatioN/A
Dividend YieldN/A
Beta1.14
ImmuCell Corporation, an animal health company, acquires, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. The company sells its products through animal health distributors. ImmuCell Corporation was founded in 1982 and is headquartered in Portland, Maine.

Headlines

ImmuCell Corp. to Host Earnings Call - Yahoo Finance
February 23, 2021 |  finance.yahoo.com
ImmuCell Corp. to Host Earnings Call
February 23, 2021 |  finance.yahoo.com
ImmuCell EPS beats by $0.04, beats on revenue
November 12, 2020 |  seekingalpha.com
ImmuCell Corporation Common Stock (ICCC)
November 2, 2020 |  nasdaq.com
How Much Does ImmuCell's (NASDAQ:ICCC) CEO Make?
October 19, 2020 |  finance.yahoo.com
ImmuCell reports Q3 preliminary sales
October 6, 2020 |  seekingalpha.com
ImmuCell EPS misses by $0.01, misses on revenue
August 12, 2020 |  seekingalpha.com
See More Headlines

Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ICCC
CUSIPN/A
Phone207-878-2770
Employees53
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$13.72 million
Cash Flow$0.20 per share
Book Value$4.02 per share

Profitability

Net Income$-1,300,000.00

Miscellaneous

Market Cap$65.49 million
Next Earnings Date5/12/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

1.28 out of 5 stars

Medical Sector

804th out of 1,972 stocks

Diagnostic Substances Industry

13th out of 32 stocks

Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$9.08
-0.27 (-2.89 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ICCC News and Ratings via Email

Sign-up to receive the latest news and ratings for ICCC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











ImmuCell (NASDAQ:ICCC) Frequently Asked Questions

Is ImmuCell a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ImmuCell in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ImmuCell stock.
View analyst ratings for ImmuCell
or view top-rated stocks.

What stocks does MarketBeat like better than ImmuCell?

Wall Street analysts have given ImmuCell a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but ImmuCell wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting ImmuCell?

ImmuCell saw a increase in short interest in January. As of January 29th, there was short interest totaling 7,700 shares, an increase of 63.8% from the January 14th total of 4,700 shares. Based on an average daily trading volume, of 37,100 shares, the short-interest ratio is presently 0.2 days. Approximately 0.2% of the company's shares are short sold.
View ImmuCell's Short Interest
.

When is ImmuCell's next earnings date?

ImmuCell is scheduled to release its next quarterly earnings announcement on Wednesday, May 12th 2021.
View our earnings forecast for ImmuCell
.

How were ImmuCell's earnings last quarter?

ImmuCell Co. (NASDAQ:ICCC) released its earnings results on Tuesday, February, 23rd. The biotechnology company reported $0.03 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.04) by $0.07. ImmuCell had a negative trailing twelve-month return on equity of 5.32% and a negative net margin of 9.99%.
View ImmuCell's earnings history
.

How has ImmuCell's stock price been impacted by Coronavirus (COVID-19)?

ImmuCell's stock was trading at $4.30 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ICCC stock has increased by 111.2% and is now trading at $9.08.
View which stocks have been most impacted by COVID-19
.

What guidance has ImmuCell issued on next quarter's earnings?

ImmuCell issued an update on its first quarter 2021 After-Hours earnings guidance on Monday, February, 22nd. The company provided EPS guidance of for the period. The company issued revenue guidance of $3.772-3.772 million, compared to the consensus revenue estimate of $5.4 million.

What price target have analysts set for ICCC?

1 brokers have issued 12 month price targets for ImmuCell's stock. Their forecasts range from $14.00 to $14.00. On average, they expect ImmuCell's stock price to reach $14.00 in the next year. This suggests a possible upside of 54.2% from the stock's current price.
View analysts' price targets for ImmuCell
or view top-rated stocks among Wall Street analysts.

Who are ImmuCell's key executives?

ImmuCell's management team includes the following people:
  • Mr. Michael F. Brigham, Pres, CEO, Principal Financial Officer, Treasurer, Sec. & Director (Age 60, Pay $344.03k)
  • Dr. Joseph H. Crabb Ph.D., VP & Chief Scientific Officer (Age 66, Pay $53.38k)
  • Ms. Bobbi Jo Brockmann, VP of Sales & Marketing and Director (Age 44, Pay $289.91k)
  • Ms. Elizabeth L. Williams, VP of Manufacturing Operations (Age 65, Pay $251.59k)
  • Elizabeth S. Toothaker, Director of Fin. & Admin.
  • Mr. A. Gustavo Scaffa, Sr. Director of Quality
  • John W. Zinckgraf, Director of Product Devel.

Who are some of ImmuCell's key competitors?

What other stocks do shareholders of ImmuCell own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ImmuCell investors own include VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Agile Therapeutics (AGRX), Biocept (BIOC), Amarin (AMRN), CorMedix (CRMD), CRISPR Therapeutics (CRSP), Genocea Biosciences (GNCA), Idera Pharmaceuticals (IDRA) and Pfizer (PFE).

What is ImmuCell's stock symbol?

ImmuCell trades on the NASDAQ under the ticker symbol "ICCC."

Who are ImmuCell's major shareholders?

ImmuCell's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (2.33%), HighTower Advisors LLC (0.23%) and Prosperity Planning Inc. (0.21%). Company insiders that own ImmuCell stock include David Cunningham and David Scott Tomsche.
View institutional ownership trends for ImmuCell
.

Which institutional investors are buying ImmuCell stock?

ICCC stock was acquired by a variety of institutional investors in the last quarter, including Prosperity Planning Inc., Renaissance Technologies LLC, and HighTower Advisors LLC. Company insiders that have bought ImmuCell stock in the last two years include David Cunningham, and David Scott Tomsche.
View insider buying and selling activity for ImmuCell
or or view top insider-buying stocks.

How do I buy shares of ImmuCell?

Shares of ICCC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ImmuCell's stock price today?

One share of ICCC stock can currently be purchased for approximately $9.08.

How much money does ImmuCell make?

ImmuCell has a market capitalization of $65.49 million and generates $13.72 million in revenue each year. The biotechnology company earns $-1,300,000.00 in net income (profit) each year or ($0.19) on an earnings per share basis.

How many employees does ImmuCell have?

ImmuCell employs 53 workers across the globe.

What is ImmuCell's official website?

The official website for ImmuCell is www.immucell.com.

Where are ImmuCell's headquarters?

ImmuCell is headquartered at 56 EVERGREEN DR, PORTLAND ME, 04103.

How can I contact ImmuCell?

ImmuCell's mailing address is 56 EVERGREEN DR, PORTLAND ME, 04103. The biotechnology company can be reached via phone at 207-878-2770 or via email at [email protected]


This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.